SEC Form 4 · accession 0001203311-17-000090
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Dobmeier
Officer — Chief Operating Officer
Period of report
Nov 15, 2017
Accepted (ET)
Nov 17, 2017 · 8:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 15, 2017 | M | 9,600 | $15.46 | A | 127,024 | D | |
| Common StockF2,F1 | Nov 15, 2017 | S | 9,600 | $57.7955 | D | 117,424 | D | |
| Common StockF1 | Nov 16, 2017 | M | 6,911 | $26.10 | A | 124,335 | D | |
| Common StockF3,F1 | Nov 16, 2017 | S | 6,911 | $57.98 | D | 117,424 | D | |
| Common StockF1 | Nov 16, 2017 | M | 8,489 | $15.46 | A | 125,913 | D | |
| Common StockF1 | Nov 16, 2017 | S | 8,489 | $57.95 | D | 117,424 | D | |
| Common StockF1 | Nov 17, 2017 | M | 10,000 | $26.10 | A | 127,424 | D | |
| Common StockF4,F1 | Nov 17, 2017 | S | 10,000 | $59.125 | D | 117,424 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $15.46 | Nov 15, 2017 | M | 9,600 | D | — | Aug 24, 2021 | Common Stock | 9,600 | 8,489 | D |
| Non-Qualified Stock Option (right to buy)F5 | $15.46 | Nov 16, 2017 | M | 8,489 | D | — | Aug 24, 2021 | Common Stock | 8,489 | 0 | D |
| Non-Qualified Stock Option (right to buy)F6 | $26.10 | Nov 16, 2017 | M | 6,911 | D | — | Aug 20, 2022 | Common Stock | 6,911 | 38,429 | D |
| Non-Qualified Stock Option (right to buy)F6 | $26.10 | Nov 17, 2017 | M | 10,000 | D | — | Aug 20, 2022 | Common Stock | 10,000 | 28,429 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $57.75 to $57.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $57.95 to $58.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $59.00 to $59.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Shares vested at a rate of 25% on 8/24/12 and monthly thereafter until all the shares were fully vested on 8/24/15.
- F6Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16.